SCHEMBL1279155

SCHEMBL1279155

N#CCC(=O)Nc1nnc(-c2ccccc2)s1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 3/20 0.61
NPC1 O15118 6/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
RAB9A P51151 6/20 0.57
TSHR P16473 2/20 0.54
KDM4E B2RXH2 4/20 0.53
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
CSNK2A2 P19784 2/20 0.53
CSNK2A1 P68400 2/20 0.53
ALDH1A1 P00352 3/20 0.53
MAPT P10636 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
HSD17B10 Q99714 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
LMNA P02545 1/20 0.52
HPGD P15428 1/20 0.51
GAA P10253 1/20 0.51
TAS2R14 Q9NYV8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6372619 0.83 DDX3X (0.56) USP30NPC1SMN1; SMN2RAB9AKDM4E
SCHEMBL29047597 0.83 SMN1; SMN2 (0.67) NPC1SMN1; SMN2RAB9ATSHRKDM4E
SCHEMBL29047532 0.82 KMT2A (0.70) NPC1SMN1; SMN2RAB9ATSHRKDM4E
SCHEMBL29047628 0.81 HDAC1 (0.63) NPC1SMN1; SMN2RAB9ATSHRKDM4E
SCHEMBL7929987 0.81 NPC1 (0.63) USP30NPC1SMN1; SMN2RAB9ATSHR
SCHEMBL14962997 0.81 KDM4E (0.76) NPC1SMN1; SMN2RAB9ATSHRKDM4E
SCHEMBL231006 0.81 NPC1 (0.63) NPC1SMN1; SMN2RAB9ATSHRKDM4E
SCHEMBL14954988 0.81 NPC1 (0.63) NPC1SMN1; SMN2RAB9ATSHRKDM4E
SCHEMBL29047581 0.80 KDM4E (0.70) NPC1SMN1; SMN2RAB9AKDM4EKMT2A
SCHEMBL29047560 0.78 KDM4E (0.67) NPC1SMN1; SMN2RAB9ATSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108947931-B Thiazole amide compound, preparation method thereof, pharmaceutical composition and application 中国科学院上海有机化学研究所 2023-07-07 CN disclosed
US-9247759-B2 Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof SENOMYX, INC. (US) 2016-02-02 US disclosed
US-20130345222-A1 IDENTIFICATION OF HUMAN T2R RECEPTORS THAT RESPOND TO BITTER COMPOUNDS THAT ELICIT THE BITTER TASTE IN COMPOSITIONS, AND THE USE THEREOF IN ASSAYS TO IDENTIFY COMPOUNDS THAT INHIBIT (BLOCK) BITTER TASTE IN COMPOSITIONS AND USE THEREOF FIRMENICH INCORPORATED 2013-12-26 US disclosed
US-20130183252-A1 COMPOUNDS THAT INHIBIT (BLOCK) BITTER TASTE IN COMPOSITION AND METHODS OF MAKING SAME SENOMYX, INC. (US) 2013-07-18 US disclosed
US-8445692-B2 Compounds that inhibit (block) bitter taste in composition and use thereof SENOMYX INC. (US) 2013-05-21 US disclosed
US-20120088796-A1 COMPOUNDS THAT INHIBIT (BLOCK) BITTER TASTE IN COMPOSITION AND USE THEREOF SENOMYX, INC. (US) 2012-04-12 US disclosed
US-8148544-B2 Compounds that inhibit (block) bitter taste in composition and methods of making same SENOMYX, INC. (US) 2012-04-03 US disclosed
US-8076491-B2 Compounds that inhibit (block) bitter taste in composition and use thereof SENOMYX, INC. (US) 2011-12-13 US disclosed
WO-2011106114-A1 IDENTIFICATION OF HUMAN T2R RECEPTORS AND THE USE THEREOF TO IDENTIFY INHIBITORS (BLOCKERS) OF BITTER TASTE SENOMYX, INC. (US) 2011-09-01 WO disclosed
US-20110207937-A1 Compounds that inhibit (block) bitter taste in composition and methods of making same SENOMYX, INC. (US) 2011-08-25 US disclosed
US-7939671-B2 Compounds that inhibit (block) bitter taste in composition and use thereof SENOMYX, INC. (US) 2011-05-10 US disclosed
US-20100254916-A1 Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof SENOMYX, INC. (US) 2010-10-07 US disclosed
EP-2195656-A2 HUMAN T2R BITTERNESS RECEPTORS AND USES THEREOF Senomyx, Inc. (US) 2010-06-16 EP disclosed
US-20090274632-A1 Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof SENOMYX, INC. (US) 2009-11-05 US disclosed
WO-2009025793-A2 HUMAN T2R BITTERNESS RECEPTORS AND USES THEREOF SENOMYX, INC. (US) 2009-02-26 WO disclosed
WO-2005072731-A1 3-PHENYL-N- ((1, 3, 4) THIADIAZOL-2-YL) -ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF ESTROGEN-RELATED RECEPTORS FOR THE TREATMENT OF E.G. CANCER, RHEUMATOID ARTHRITIS OR NEUROLOGICAL DISORDERS X-CEPTOR THERAPEUTICS, INC. (US) 2005-08-11 WO disclosed
WO-2005072731-A1 3-PHENYL-N- ((1, 3, 4) THIADIAZOL-2-YL) -ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF ESTROGEN-RELATED RECEPTORS FOR THE TREATMENT OF E.G. CANCER, RHEUMATOID ARTHRITIS OR NEUROLOGICAL DISORDERS X-CEPTOR THERAPEUTICS, INC. (US) 2005-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207937-A1 Compounds that inhibit (block) bitter taste in composition and methods of making same TAS2R50, TAS2R1, TAS2R5 USP30 3622/4885NPC1 3309/4885SMN1; SMN2 4391/4885
US-20090274632-A1 Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof TAS2R50, TAS2R1, TAS2R30 USP30 3247/4885NPC1 3331/4885SMN1; SMN2 4469/4885
US-20120088796-A1 COMPOUNDS THAT INHIBIT (BLOCK) BITTER TASTE IN COMPOSITION AND USE THEREOF TAS2R50, TAS2R5, TAS2R1 USP30 3837/4885NPC1 3407/4885SMN1; SMN2 4412/4885
US-20100254916-A1 Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof TAS2R50, TAS2R1, TAS2R30 USP30 3199/4885NPC1 3334/4885SMN1; SMN2 4463/4885
US-20130183252-A1 COMPOUNDS THAT INHIBIT (BLOCK) BITTER TASTE IN COMPOSITION AND METHODS OF MAKING SAME TAS2R50, TAS2R1, TAS2R5 USP30 3622/4885NPC1 3309/4885SMN1; SMN2 4391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.